Article Details
Retrieved on: 2022-02-14 20:02:58
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... evaluated in phase 1/2 clinical trials, according to a recent announcement by Immunomic Therapeutics, Inc, developer of ITI-300 and ITI-1000.
Article found on: www.targetedonc.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here